However, our results show that a “gain of function” strategy to increase Prnp dosage in Alzheimer's disease or a “loss of function” in case of prionopathies to prevent PrPc to PrPsc conversion may impair natural function or PrPc leading to devastating effects if natural expression levels are modified. Here, PRNP is linked to early-onset autosomal dominant Alzheimer disease.